Women's Health Policy

ABORTION IN THE U.S.

KFF infographic explaining who regulates mifepristone, showing four entities and their roles: the U.S. Food and Drug Administration approves and regulates medications for safety and effectiveness; state legislatures pass laws that can restrict or protect access; courts rule on legal cases affecting regulation; and Congress can pass federal legislation influencing regulation.

Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

Louisiana sued the FDA in October 2025, claiming the FDA’s 2023 regulatory change eliminating the requirement that mifepristone be dispensed in-person—allowing it to be mailed or dispensed at retail pharmacies—harm the state's ability to enforce its abortion ban. This brief reviews the Louisiana v. FDA case now before the Supreme Court, and provides an overview of the other pending litigation involving mifepristone, as well as the mounting tension between states seeking to protect abortion and those banning the provision of abortion.

CONTRACEPTIve care IN THE U.S.

New and noteworthy

Over-the-Counter Oral Contraceptive Pills

In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

381 - 390 of 870 Results

  • President Trump’s Record on Health Care

    Issue Brief

    This issue brief provides a detailed overview of the Trump Administration’s record on health care issues relating to: the Administration’s response to the COVID-19 pandemic, the ACA and private insurance markets, Medicaid, Medicare, reducing prescription drug and other health care costs, sexual and reproductive health, mental health and substance use, immigration and health, long-term care, HIV/AIDS policy, and LGBTQ health.

  • Contraception X Article: Out-of-Pocket Spending for Oral Contraceptives Among Women with Private Insurance Coverage After the Affordable Care Act

    Issue Brief

    In an article for Contraception X, KFF's Brittni Frederiksen, Matthew Rae, and Alina Salganicoff examine large employer plans to identify which types and brands of oral contraceptive pills have the largest shares of oral contraceptive users with out-of-pocket spending and which oral contraceptives have the highest average annual out-of-pocket costs after the ACA covered contraception under it's preventive services provisions.

  • Amid the Coronavirus Crisis, President Trump and Democratic Nominee Joe Biden Offer Widely Different Views on Health Care

    News Release

    President Trump and Democratic nominee Joe Biden hold widely divergent views on health issues, with the president’s record and response to the coronavirus pandemic likely to play a central role in November’s elections. A new KFF side-by-side comparison examines President Trump’s record and former Vice President Biden’s positions across a wide range of key health issues, including the response to the pandemic, the Affordable Care Act marketplace, Medicaid, Medicare, drug prices, reproductive health, HIV, mental…

  • State Action to Limit Abortion Access During the COVID-19 Pandemic

    Issue Brief

    This data note presents an interactive map that tracks which states have made declarations defining abortions as non-essential or elective health procedures and effectively blocking the provision of abortion services during the outbreak.

  • Abortion Back at the Supreme Court: June Medical Services LLC v. Russo

    Issue Brief

    This issue brief explains the legal and factual issues in dispute and the reviews the potential implications of different rulings in the case of June Medical Services v. Russo, which could have significant implications for women’s access to abortion and could eliminate the right of abortion providers to bring legal challenges to state and federal laws and policies.

  • Potential Impacts of Delaying “Non-Essential” Reproductive Health Care

    Issue Brief

    This brief analyzes how states, health systems and providers have been faced with deciding what health care is “essential” verses “elective” during the COVID-19 crisis, and what the possible consequences are to delays in "non-essential" reproductive health care.

  • At-Home SARS-CoV-2 Testing: What Are the Options?

    Interactive

    This interactive table includes vendors selling at-home SARS-CoV-2 diagnostic tests that have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).